{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:43:29Z","timestamp":1761155009461},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":4583,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prior to the development of intensive treatments for patients with advanced stage B\u2010cell non\u2010Hodgkin's lymphoma (B\u2010NHL), the prognosis for such patients was dismal. A minority of patients attained long\u2010term, disease\u2010free survival. Since 1981, we have treated 28 children with advanced stage B\u2010NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high\u2010dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high\u2010dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B\u2010cell acute lymphoblastic leukemia and 26 had stage III B\u2010NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B\u2010ALL and 21 of 26 with stage III B\u2010NHL remain in CR, with a median follow\u2010up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T\u2010cell lymphoblastic lymphoma 4 1\/2 years after the diagnosis of B\u2010NHL. The 2\u2010 and 5\u2010year event\u2010free survival rates were 85.7 \u00b1 6.6% (SE) and 79.6 \u00b1 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B\u2010NHL without CNS involvement. \u00a9 1994 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/mpo.2950230502","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T19:08:59Z","timestamp":1171998539000},"page":"393-399","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of advanced stage diffuse, small non\u2010cleaved cell lymphoma in childhood: Further experience with total therapy B"],"prefix":"10.1002","volume":"23","author":[{"given":"Timothy C.","family":"Griffin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Paul","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi J.","family":"Winick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George R.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(75)90597-5"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303103081003"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.5.1102.1102"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.8.1219"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"e_1_2_1_7_2","unstructured":"Muller\u2010WeihrichST LudwigR ReiterA: B\u2010type non\u2010Hodgkin's lymphoma and leukemia. The BFM study group experience. 3rd International Conference on Malignant Lymphoma Lugano 1987(abstr)."},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950170107"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.133"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"e_1_2_1_11_2","first-page":"1161","article-title":"Management of childhood non\u2010Hodgkin's lymphoma","volume":"61","author":"Murphy SB","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_1_13_2","first-page":"277","article-title":"Improved survival for children with B\u2010cell (SIg+) acute lymphoblastic leukemia (B\u2010ALL) and stage IV small, noncleaved cell lymphoma (SNCCL)","volume":"11","author":"Bowman WP","year":"1992","journal-title":"Proc ASCO"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950230502","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950230502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T01:24:55Z","timestamp":1698197095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950230502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1002\/mpo.2950230502"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950230502","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}